NASDAQ$PLRX
Pliant Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Pliant Therapeutics reported a net loss of $56.166 million for Q1 2025, with a basic and diluted net loss per share of $0.92. The company's total assets were $344.770 million.
Pliant Therapeutics, Inc. reported a net loss of $56.166 million for the three months ended March 31, 2025, compared to a net loss of $46.955 million for the same period in 2024. The loss from operations increased to $58.935 million from $52.392 million in the prior year. The company's cash and cash equivalents decreased to $91.936 million from $71.188 million at the end of 2024, and total assets were $344.770 million.
- Net loss increased to $56.166 million in Q1 2025 from $46.955 million in Q1 2024.
- Research and development expenses increased by $6.290 million, primarily due to close-out activities for BEACON-IPF and employee-related expenses.
- The company discontinued the BEACON-IPF Phase 2b trial due to an imbalance in safety events, but topline data is still expected in Q2 2025.
- The company announced a strategic workforce reduction of approximately 45% on May 1, 2025, expecting to recognize $3.6 million in severance and related benefits.
Headline financials
Revenue & EPS history
Pliant Therapeutics · Revenue · Quarterly
$0
Forward guidance
Pliant Therapeutics expects to continue incurring significant net losses for the foreseeable future due to ongoing research and development activities. The company anticipates a decrease in research and development expenses in the near term due to the discontinuation of the BEACON-IPF trial, with a re-prioritization of earlier-stage development programs. General and administrative expenses are expected to remain relatively consistent.
Tailwinds
- Plans to analyze complete data from the BEACON-IPF trial to evaluate next steps for bexotegrast's development.
- Interim Phase 1 data from PLN-101095 and pembrolizumab demonstrated antitumor activity with confirmed partial responses.
- PLN-101325 is Phase 1-ready for muscular dystrophies and has received clinical trial approval in Australia.
- Strategic realignment of workforce and operations is underway to extend cash runway and support clinical trials.
- Existing cash, cash equivalents, and short-term investments are believed to be sufficient to fund anticipated operating expenses and capital expenditure requirements for the next 12 months and beyond.
Headwinds
- Expects to continue to incur significant net losses for the foreseeable future.
- Will require substantial additional capital to fund operations, which may be difficult to obtain on acceptable terms.
- Discontinuation of the BEACON-IPF Phase 2b trial due to an imbalance in safety events.
- Future capital requirements and the period for which existing resources will support operations may vary significantly from expectations.
- The discontinuation of the BEACON-IPF trial may intensify the risk of being unable to access capital on favorable terms.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-1.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
-4.2%
Avg return
30 days after
36%
9 / 25 earnings
Positive
+12.1%
Q3 2020
Best reaction
-11.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.8% | -4.2% | -4.2% | |
| Q3 2025 | +3.3% | +17.6% | -20.9% | |
| Q1 2025 | -1.5% | -2.9% | -1.4% | |
| Q4 2024 | -11.7% | +17.4% | -5.1% | |
| Q3 2024 | -4.5% | -12.0% | -6.4% | |
| Q2 2024 | -6.5% | -9.6% | -1.8% | |
| Q1 2024 | -1.4% | -1.2% | -13.4% | |
| Q4 2023 | -7.8% | -4.8% | -13.4% | |
| Q3 2023 | -8.0% | -12.4% | -2.7% | |
| Q2 2023 | +3.4% | -0.9% | -9.5% | |
| Q1 2023 | +4.2% | -0.0% | +3.0% | |
| Q4 2022 | -10.9% | -9.4% | -17.6% | |
| Q3 2022 | -6.5% | -6.7% | -14.5% | |
| Q2 2022 | +11.9% | +12.6% | +6.2% | |
| Q1 2022 | -6.8% | -1.8% | +40.5% | |
| Q4 2021 | +3.7% | -9.9% | -26.6% | |
| Q3 2021 | -4.0% | -3.2% | -17.9% | |
| Q2 2021 | -6.5% | -12.4% | -15.7% | |
| Q1 2021 | -0.1% | -14.7% | -3.1% | |
| Q4 2020 | +4.6% | +2.5% | -19.9% | |
| Q3 2019 | +12.1% | +9.9% | +21.2% | |
| Q3 2020 | +12.1% | +9.9% | +21.2% | |
| Q2 2020 | -8.5% | -8.2% | -1.2% | |
| Q4 2019 | -8.5% | -8.2% | -1.2% | |
| Q2 2019 | -8.5% | -8.2% | -1.2% | |
| Q1 2020 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro